SCNI

Scinai Immunotherapeutics
SCNI

Overview Fund Trends Analyst Outlook Journalist POV

10 hedge funds and large institutions have $309K invested in Scinai Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

less ownership

Funds ownership: →

less capital invested

Capital invested by funds: $ → $

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
10
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$14.9K
2
+$4.76K

Top Sellers

1
-$190K
2
-$43.5K
3
-$23K
4
UBS Group
UBS Group
Switzerland
-$6.97K
5
Morgan Stanley
Morgan Stanley
New York
-$113
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$269K
2
$15.7K
3
$14.9K
4
$4.76K
5
$3.08K
6
$598
7
$431
8
$226
9
$71
10
$28
11
$3
12
–